- Home
- CYN vs QNRX Comparison
CYN vs QNRX Comparison
Compare CYN & QNRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CYN | QNRX |
|---|---|---|
| Founded | 2013 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Medical/Dental Instruments |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.5M | 14.5M |
| IPO Year | 2021 | 2023 |
Fundamental Metrics
Financial Performance| Metric | CYN | QNRX |
|---|---|---|
| Price | $1.50 | $8.77 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 390.8K | 21.2K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $368,138.00 | N/A |
| Revenue This Year | $31.96 | N/A |
| Revenue Next Year | $1,459.25 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.33 | $0.21 |
| 52 Week High | $41.54 | $41.80 |
Technical Indicators
Market Signals| Indicator | CYN | QNRX |
|---|---|---|
| Relative Strength Index (RSI) | 38.90 | 48.37 |
| Support Level | $1.33 | $8.03 |
| Resistance Level | $2.76 | $10.05 |
| Average True Range (ATR) | 0.11 | 0.74 |
| MACD | 0.04 | 0.16 |
| Stochastic Oscillator | 45.12 | 30.42 |
Price Performance
Historical ComparisonAbout CYN Cyngn Inc.
Cyngn Inc is an industrial autonomous vehicle technology company. Its flagship innovation is DriveMod, an autonomous driving solution that can be flexibly deployed on multiple vehicle types manufactured by Original Equipment Manufacturers in various environments.
About QNRX Quoin Pharmaceuticals Ltd.
Quoin Pharmaceuticals Ltd is a clinical stage specialty pharmaceutical company focused on developing and commercializing therapeutic products that treat rare and orphan diseases. Its pipeline comprises three products that collectively have the potential to target a broad number of rare and orphan indications, including Netherton Syndrome, Peeling Skin Syndrome, Palmoplantar Keratoderma, Epidermolysis Bullosa, and others.